In Vitro Examination of the Thrombolytic Efficacy of Tenecteplase and Therapeutic Ultrasound Compared to Rt-PA

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2019 Aug 4

PMID 31375069

Citations 6

Authors

Tobias Fruhwald

Ulrich Gartner

Nils Stockmann

Jan-Henning Marxsen

Carolin Gramsch

Florian C Roessler

Affiliations

Soon will be listed here.

Abstract

Background: Optimizing thrombolytic therapy is vital for improving stroke outcomes. We aimed to develop standardized thrombolysis conditions to evaluate the efficacy of tenecteplase (TNK) compared to the current gold standard rt-PA (alteplase), with and without additional ultrasound treatment. We also wanted to introduce a new analytical approach to quantify fibrin fiber density in transmission electron microscopy (TEM).

Methods: In vitro clots that are similar to ex vivo clots concerning their histological condition and their durability were generated from whole blood. For five treatment groups we compared relative clot weight loss (each n = 60) and fibrin fiber density in TEM (each n = 5). The control group (A) was treated only with plasma. Two groups were designated for each rt-PA (B + C) and TNK (D + E). Groups C and E were additionally treated with ultrasound. Dosages were 50 μg/ml for rt-PA and 30 μg/ml for TNK. Results were evaluated by using analyses of variance (ANOVA) and post-hoc t-tests.

Results: Weight loss was increased significantly for all groups compared to the control group. Both TNK groups showed significantly increased weight loss compared to their counterpart rt-PA group (p ≤ 0.001). For TEM only group D showed significantly decreased fibrin fiber density (p < 0.05) compared to both rt-PA groups. Ultrasound did not significantly increase dissolution of clots with either method (best p = 0.16).

Conclusions: Tenecteplase dissolved clots more effectively than rt-PA with and without ultrasound. A higher sample size could provide more convincing results for TEM.

Citing Articles

Intravenous Thrombolysis with Urokinase for Acute Ischemic Stroke.

Qiao Y, Wang J, Nguyen T, Liu L, Ji X, Zhao W Brain Sci. 2024; 14(10).

PMID: 39452001 PMC: 11505899. DOI: 10.3390/brainsci14100989.

Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.

Correa-Paz C, Perez-Mato M, Bellemain-Sagnard M, Gonzalez-Dominguez M, Marie P, Perez-Gayol L J Cereb Blood Flow Metab. 2024; 44(8):1306-1318.

PMID: 38436292 PMC: 11342720. DOI: 10.1177/0271678X241237427.

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Shen Z, Bao N, Tang M, Yang Y, Li J, Liu W Neurol Ther. 2023; 12(5):1553-1572.

PMID: 37552459 PMC: 10444744. DOI: 10.1007/s40120-023-00530-4.

The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials.

Abuelazm M, Seri A, Awad A, Ahmad U, Mahmoud A, Albazee E J Thromb Thrombolysis. 2022; 55(2):322-338.

PMID: 36449231 PMC: 10011306. DOI: 10.1007/s11239-022-02730-5.

Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke.

Estella A, Perez Ruiz M, Serrano J J Pers Med. 2022; 12(9).

PMID: 36143310 PMC: 9503588. DOI: 10.3390/jpm12091525.

References

Nasr D, Brinjikji W, Cloft H, Rabinstein A . Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke. 2012; 8(8):681-8. DOI: 10.1111/j.1747-4949.2012.00844.x. View

Holland C, Vaidya S, Datta S, Coussios C, Shaw G . Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model. Thromb Res. 2007; 121(5):663-73. PMC: 2268623. DOI: 10.1016/j.thromres.2007.07.006. View

Hitchcock K, Ivancevich N, Haworth K, Caudell Stamper D, Vela D, Sutton J . Ultrasound-enhanced rt-PA thrombolysis in an ex vivo porcine carotid artery model. Ultrasound Med Biol. 2011; 37(8):1240-51. PMC: 4025997. DOI: 10.1016/j.ultrasmedbio.2011.05.011. View

Coutts S, Berge E, Campbell B, Muir K, Parsons M . Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials. Int J Stroke. 2018; 13(9):885-892. DOI: 10.1177/1747493018790024. View

Meairs S, Alonso A, Hennerici M . Progress in sonothrombolysis for the treatment of stroke. Stroke. 2012; 43(6):1706-10. DOI: 10.1161/STROKEAHA.111.636332. View

Eggers J, Konig I, Koch B, Handler G, Seidel G . Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study. Stroke. 2008; 39(5):1470-5. DOI: 10.1161/STROKEAHA.107.503870. View

Anrather J, Iadecola C . Inflammation and Stroke: An Overview. Neurotherapeutics. 2016; 13(4):661-670. PMC: 5081118. DOI: 10.1007/s13311-016-0483-x. View

Roessler F, Teichert A, Ohlrich M, Marxsen J, Stellmacher F, Tanislav C . Development of a new clot formation protocol for standardized in vitro investigations of sonothrombolysis. J Neurosci Methods. 2014; 237:26-32. DOI: 10.1016/j.jneumeth.2014.08.025. View

Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T . Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke. 2005; 36(7):1441-6. DOI: 10.1161/01.STR.0000170707.86793.1a. View

10.

Roessler F, Wang Z, Schumacher S, Ohlrich M, Kaps M, Menciassi A . In Vitro Examination of the Thrombolytic Efficacy of Desmoteplase and Therapeutic Ultrasound Compared with rt-PA. Ultrasound Med Biol. 2015; 41(12):3233-40. DOI: 10.1016/j.ultrasmedbio.2015.07.007. View

11.

Petit B, Bohren Y, Gaud E, Bussat P, Arditi M, Yan F . Sonothrombolysis: the contribution of stable and inertial cavitation to clot lysis. Ultrasound Med Biol. 2015; 41(5):1402-10. DOI: 10.1016/j.ultrasmedbio.2014.12.007. View

12.

Eggers J, Ossadnik S, Seidel G . Enhanced clot dissolution in vitro by 1.8-MHz pulsed ultrasound. Ultrasound Med Biol. 2008; 35(3):523-6. DOI: 10.1016/j.ultrasmedbio.2008.09.009. View

13.

Logallo N, Kvistad C, Thomassen L . Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs. 2015; 29(10):811-8. DOI: 10.1007/s40263-015-0280-9. View

14.

Barlinn K, Tsivgoulis G, Barreto A, Alleman J, Molina C, Mikulik R . Outcomes following sonothrombolysis in severe acute ischemic stroke: subgroup analysis of the CLOTBUST trial. Int J Stroke. 2014; 9(8):1006-10. PMC: 4227933. DOI: 10.1111/ijs.12340. View

15.

Roessler F, Schumacher S, Sprenger A, Gartner U, Al-Khaled M, Eggers J . Clot Formation in the Presence of Acetylsalicylic Acid Leads to Increased Lysis Rates Regardless of the Chosen Thrombolysis Strategy. J Vasc Res. 2016; 53(3-4):128-137. DOI: 10.1159/000449386. View

16.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-29. DOI: 10.1056/NEJMoa0804656. View

17.

Haley Jr E, Lyden P, Johnston K, Hemmen T . A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005; 36(3):607-12. DOI: 10.1161/01.STR.0000154872.73240.e9. View

18.

Iadecola C, Anrather J . The immunology of stroke: from mechanisms to translation. Nat Med. 2011; 17(7):796-808. PMC: 3137275. DOI: 10.1038/nm.2399. View

19.

Tanswell P, Tebbe U, Neuhaus K, Wojcik J, Seifried E . Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol. 1992; 19(5):1071-5. DOI: 10.1016/0735-1097(92)90297-z. View

20.

Campbell B, Mitchell P, Churilov L, Yassi N, Kleinig T, Dowling R . Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018; 378(17):1573-1582. DOI: 10.1056/NEJMoa1716405. View